AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

1,457 drug developers and their pipelines

Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.

Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.

← browse by therapeutic area

Views

1457 of 1457 companies

CompanyPipelineMost advancedNext readoutMarket capCash & inv.RunwayR&D / yr
PRECISION BIOSCIENCES INC logo
PRECISION BIOSCIENCES INCDTIL · Nasdaq
1 asset: 1 Ph 1Azercabtagene zapreleucelPhase 1 · Multiple Sclerosis1 Dec 2026Azercabtagene zapreleucel · Phase 1$198M$108MSep 2026~8.4 qtrs$53M
Cartesian Therapeutics, Inc. logo
Cartesian Therapeutics, Inc.RNAC · Nasdaq
1 asset: 1 Ph 3Descartes-08Phase 3 · Myasthenia Gravis1 Dec 2026Descartes-08 · Phase 2$192M$125MSep 2026~5.6 qtrs$70M
Alpha Cognition Inc. logo
Alpha Cognition Inc.ACOG · Nasdaq
1 asset: 1 approvedApproved assets onlyApr 2027Benzgalantamine · Approved$187M$38MSep 2026~5.0 qtrs$5.0M
COMPUGEN LTD logo
COMPUGEN LTDCGEN · Nasdaq
3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1RilvegostomigPhase 3 · Non-Small Cell Lung CancerMar 2027COM701 · Phase 1/2$185M$100MDec 2025Cash-flow positive$23M
Inovio Pharmaceuticals, Inc. logo
Inovio Pharmaceuticals, Inc.INO · Nasdaq
1 asset: 1 approvedApproved assets onlyNone on record$175M$48MSep 2026~2.6 qtrs$46M
Pyxis Oncology logo
Pyxis OncologyPYXS · Nasdaq
2 assets: 1 Ph 3, 1 Ph 2MW02Phase 2/3 · Age-Related Macular DegenerationPartial signal25 Apr 2027Micvotabart pelidotin · Phase 1$168M$56MSep 2026~8.9 qtrswith a later raise$74M
Xilio Therapeutics logo
Xilio TherapeuticsXLO · Nasdaq
1 asset: 1 Ph 2XTX501Phase 1/2 · Non-Small Cell Lung CancerNov 2029XTX501 · Phase 1/2$154M$124MSep 2026~8.7 qtrs$67M
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) logo
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)BBOT · Nasdaq
3 assets: 3 Ph 1BBO-10203Phase 1 · Non-Small Cell Lung CancerAug 2027BBO-10203 · Phase 1$145M$194MSep 2026~5.1 qtrs$157M
Sutro Biopharma, Inc. logo
Sutro Biopharma, Inc.STRO · Nasdaq
1 asset: 1 Ph 1STRO-004Phase 1 · Non-Small Cell Lung CancerDec 2027STRO-004 · Phase 1$141M$142MSep 2026~4.4 qtrs$128M
Humacyte logo
HumacyteHUMA · Nasdaq
1 asset: 1 approvedApproved assets onlyJun 2027Human Acellular Vessel (Humacyte) · Phase 3$139M$65MSep 2026~2.9 qtrs$66M
ALX Oncology Inc. logo
ALX Oncology Inc.ALXO · Nasdaq
2 assets: 1 Ph 2, 1 Ph 1EvorpaceptPhase 2 · HER2-Positive Breast CancerJun 2027ALX2004 · Phase 1$134M$138MJun 2026~7.8 qtrs$62M
Protara Therapeutics logo
Protara TherapeuticsTARA · Nasdaq
1 asset: 1 Ph 3TARA-002Phase 3 · Non-Muscle Invasive Bladder CancerDec 2026TARA-002 · Phase 2$132M$128MSep 2026~7.1 qtrs$60M
MacroGenics logo
MacroGenicsMGNX · Nasdaq
5 assets: 1 Ph 2, 4 Ph 1LorigerlimabPhase 2Nov 2026MGD024 · Phase 1$125M$49MSep 2026~4.9 qtrs$138M
Fate Therapeutics logo
Fate TherapeuticsFATE · Nasdaq
4 assets: 1 Ph 2, 2 Ph 1, 1 otherFT819Phase 2 · Systemic Lupus Erythematosus30 Sep 2027FT819 · Phase 1$122M$139MSep 2026~5.3 qtrs$99M
NRx Pharmaceuticals logo
NRx PharmaceuticalsNRXP · Nasdaq
1 asset: 1 Ph 3D-cycloserine/lurasidone (NRX-101)Phase 3 · Bipolar DepressionNone on record$121M$27MJun 2026~5.4 qtrs$5.4M
Upstream Bio logo
Upstream BioUPB · Nasdaq
1 asset: 1 Ph 2verekitugPhase 2 · Chronic Obstructive Pulmonary DiseaseReliable signalSep 2027verekitug · Phase 2$114M$207MSep 2026~4.9 qtrs$149M
Akebia Therapeutics logo
Akebia TherapeuticsAKBA · Nasdaq
3 assets: 1 approved, 2 Ph 2Ebribafusp alfaPhase 2 · IgA NephropathyJun 2027Praliciguat · Phase 2$114M$160MSep 2026Cash-flow positive$72M
Compass Therapeutics logo
Compass TherapeuticsCMPX · Nasdaq
2 assets: 1 Ph 3, 1 Ph 1tovecimigPhase 2/3 · Biliary Tract CancerDec 2026CTX-8371 · Phase 1$110M$163MSep 2026~10.6 qtrs$69M
Minerva Neurosciences logo
Minerva NeurosciencesNERV · Nasdaq
1 asset: 1 Ph 3RoluperidonePhase 3 · SchizophreniaPartial signalDec 2027Roluperidone · Phase 3$109M$77MSep 2026~9.8 qtrs$20M
Neonc Technologies, Inc. logo
Neonc Technologies, Inc.NTHI · Nasdaq
2 assets: 1 Ph 2, 1 otherNEO212Phase 1/2 · Non-Small Cell Lung Cancer30 Dec 2026NEO100 · Phase 2$108M$6.2MSep 2026~1.2 qtrs$6.5M
Lexaria Bioscience logo
Lexaria BioscienceLEXX · Nasdaq
2 assets: 1 Ph 1, 1 otherDehydraTECH-CBD/semaglutidePhase 1 · ObesityWeak signalNone on record$106M$3.6MMay 2026Ended Oct 2026$5.3M
NovaBridge Biosciences logo
NovaBridge BiosciencesNBP · Nasdaq
2 assets: 1 Ph 3, 1 Ph 2UliledlimabPhase 2/3 · Non-Small Cell Lung CancerDec 2026givastomig · Phase 1$104M$211MDec 2025~38.3 qtrs$63M
Voyager Therapeutics logo
Voyager TherapeuticsVYGR · Nasdaq
1 asset: 1 Ph 2VY7523Phase 1/2 · Alzheimer's DiseaseNone on record$104M$110MSep 2026~4.0 qtrs$107M
Genelux Corporation logo
Genelux CorporationGNLX · Nasdaq
1 asset: 1 Ph 3Olvimulogene nanivacirepvecPhase 3 · Ovarian CancerDec 2026Olvimulogene nanivacirepvec · Phase 3$101M$19MJun 2026~3.0 qtrs$23M
Unicycive Therapeutics logo
Unicycive TherapeuticsUNCY · Nasdaq
1 asset: 1 Ph 2Oxylanthanum carbonatePhase 2 · Chronic Kidney DiseaseWeak signalNone on record$99M$61MJun 2026~8.8 qtrs$9.6M
Cumberland Pharmaceuticals Inc. logo
Cumberland Pharmaceuticals Inc.CPIX · Nasdaq
1 asset: 1 Ph 2IfetrobanPhase 2 · Systemic SclerosisPartial signalJan 2028Ifetroban · Phase 2$99M$81MSep 202610+ years$4.6M
PMV Pharmaceuticals, Inc logo
PMV Pharmaceuticals, IncPMVP ·
1 asset: 1 Ph 2rezatapoptPhase 1/2 · Non-Small Cell Lung Cancer15 Dec 2026rezatapopt · Phase 1/2$92M$103MSep 2026~5.9 qtrs$62M
TuHURA Biosciences logo
TuHURA BiosciencesHURA · Nasdaq
1 asset: 1 Ph 3IFx-2.0Phase 2/3 · Merkel Cell Carcinoma31 Mar 2027IFx-2.0 · Phase 2/3$87M$1.9MSep 2026Ended Oct 2026$22M
RANI Therapeutics logo
RANI TherapeuticsRANI · Nasdaq
1 asset: 1 Ph 1RT-114Phase 11 Dec 2026RT-114 · Phase 1$80M$3.8MSep 2026~0.7 qtrs$21M
M
Maia BiotechnologyMAIA · NYSE
1 asset: 1 Ph 3Ateganosine (THIO)Phase 3 · Non-Small Cell Lung Cancer31 Jul 2027Ateganosine (THIO) · Phase 3$79M$0Sep 2026Ended Sep 2026-$2.7M
Tenax Therapeutics logo
Tenax TherapeuticsTENX · Nasdaq
1 asset: 1 Ph 3LevosimendanPhase 3 · Heart FailurePartial signal30 Jun 2028Levosimendan · Phase 3$77M$114MSep 2026~9.2 qtrs$47M
Neumora Therapeutics, Inc. logo
Neumora Therapeutics, Inc.NMRA · Nasdaq
1 asset: 1 Ph 1NMRA-323511Phase 1 · Alzheimer's DiseasePartial signalNone on record$69M$117MJun 2026~2.6 qtrs$153M
Anavex Life Sciences logo
Anavex Life SciencesAVXL · Nasdaq
2 assets: 1 Ph 3, 1 Ph 2BlarcamesinePhase 2/3 · Alzheimer's DiseasePartial signalNone on record$67M$118MJun 2026~13.8 qtrs$32M
MediciNova, Inc. logo
MediciNova, Inc.MNOV · Nasdaq
2 assets: 1 Ph 3, 1 Ph 2IbudilastPhase 2/3 · Amyotrophic Lateral Sclerosis31 Dec 2026Tipelukast · Phase 2$65M$29MSep 2026~11.9 qtrs$4.7M
vTv Therapeutics logo
vTv TherapeuticsVTVT · Nasdaq
3 assets: 2 Ph 3, 1 Ph 2Prifemilast (HPP737)Phase 3 · PsoriasisPartial signalApr 2027cadisegliatin · Phase 3$64M$77MSep 2026~14.2 qtrs$29M
Coherus BioSciences, Inc. logo
Coherus BioSciences, Inc.CHRS · Nasdaq
1 asset: 1 approvedApproved assets only15 Dec 2026Toripalimab · Phase 1$63M$84MSep 2026~1.9 qtrs$97M
Longeveron (NASDAQ: LGVN) logo
Longeveron (NASDAQ: LGVN)LGVN · Nasdaq
1 asset: 1 Ph 2LaromestrocelPhase 2 · Alzheimer's DiseaseWeak signalNone on record$60M$7.3MSep 2026~1.6 qtrs$12M
Cognition Therapeutics logo
Cognition TherapeuticsCGTX · Nasdaq
1 asset: 1 Ph 2ZervimesinePhase 2 · Alzheimer's DiseaseWeak signal31 May 2027Zervimesine · Phase 2$57M$31MSep 2026~8.2 qtrs$27M
Corbus Pharmaceuticals logo
Corbus PharmaceuticalsCRBP · Nasdaq
2 assets: 1 Ph 3, 1 Ph 1Sutantatug envedotinPhase 3 · Cervical Cancer16 Jan 2027Sutantatug envedotin · Phase 1/2$57M$115MSep 2026~5.0 qtrs$104M
Oncolytics Biotech Inc. logo
Oncolytics Biotech Inc.ONCY · Nasdaq
1 asset: 1 Ph 2PelareorepPhase 2 · Advanced Metastatic Colorectal Cancer30 Jul 2027Pelareorep · Phase 1/2$56M$2.4MSep 2026Ended Oct 2026~$19M
Tonix Pharmaceuticals logo
Tonix PharmaceuticalsTNXP · Nasdaq
5 assets: 3 approved, 2 Ph 2TNX-1300Phase 2 · Cocaine IntoxicationFeb 2028cyclobenzaprine · Phase 2$55M$163MSep 2026~3.9 qtrs$80M
Veru Inc. logo
Veru Inc.VERU · Nasdaq
1 asset: 1 Ph 2enobosarmPhase 2 · ObesityPartial signalOct 2027enobosarm · Phase 2$53M$24MJun 2026~3.1 qtrs$16M
Werewolf Therapeutics, Inc. logo
Werewolf Therapeutics, Inc.HOWL ·
2 assets: 1 Ph 2, 1 Ph 1WTX-330Phase 1/2 · Advanced Solid Tumors and Non-Hodgkin LymphomaNone on record$50M$42MSep 2026~7.0 qtrs$23M
Gain Therapeutics, Inc. logo
Gain Therapeutics, Inc.GANX · Nasdaq
1 asset: 1 Ph 2GT-02287Phase 2 · Parkinson's Disease30 Jun 2028GT-02287 · Phase 2$49M$12MSep 2026~2.7 qtrs$8.7M
Clene Nanomedicine logo
Clene NanomedicineCLNN · Nasdaq
1 asset: 1 Ph 3CNM-Au8Phase 2/3 · Multiple SclerosisPartial signalNone on record$48M$10.0MSep 2026~2.4 qtrs$14M
Apollomics Inc. logo
Apollomics Inc.APLM · Nasdaq
1 asset: 1 Ph 3VebreltinibPhase 3 · Non-Small Cell Lung CancerWeak signal31 Dec 2026Vebreltinib · Phase 1/2$48M$3.3MDec 2025~4.1 qtrswith a later raise$5.5M
Mereo BioPharma logo
Mereo BioPharmaMREO · Nasdaq
2 assets: 1 Ph 3, 1 Ph 2setrusumabPhase 3 · Osteogenesis ImperfectaPartial signalJan 2027setrusumab · Phase 3$46M$26MSep 2026~4.0 qtrs$13M
MiNK Therapeutics, Inc. logo
MiNK Therapeutics, Inc.INKT · Nasdaq
1 asset: 1 Ph 2agenT-797Phase 2 · Gastric CancerWeak signalJun 2027agenT-797 · Phase 2$45M$7.5MSep 2026~4.2 qtrs$6.4M
Pliant Therapeutics, Inc. logo
Pliant Therapeutics, Inc.PLRX ·
1 asset: 1 Ph 1PLN-101095Phase 1 · Non-Small Cell Lung CancerJun 2030PLN-101095 · Phase 1$41M$143MSep 2026~8.5 qtrs$64M
Aldeyra Therapeutics logo
Aldeyra TherapeuticsALDX · Nasdaq
1 asset: 1 Ph 3reproxalapPhase 3 · Dry Eye DiseasePartial signalNone on record$41M$41MSep 2026~8.6 qtrs$12M
Biomea Fusion logo
Biomea FusionBMEA · Nasdaq
2 assets: 1 Ph 2, 1 Ph 1IcovamenibPhase 2 · Type 2 DiabetesPartial signalMar 2027Icovamenib · Phase 2$39M$27MSep 2026~2.4 qtrs$35M
Skye Bioscience logo
Skye BioscienceSKYE · Nasdaq
1 asset: 1 Ph 2nimacimabPhase 2 · ObesityNone on record$36M$4.8MSep 2026~0.6 qtrs$25M
Grace Therapeutics logo
Grace TherapeuticsGRCE · Nasdaq
1 asset: 1 Ph 3Nimodipine (GTx-104)Phase 3 · Subarachnoid HemorrhageNone on record$36M$21MSep 2026~8.2 qtrs~$2.6M
Annovis Bio (NYSE American: ANVS) logo
Annovis Bio (NYSE American: ANVS)ANVS · NYSE American
1 asset: 1 Ph 3BuntanetapPhase 3 · Alzheimer's DiseasePartial signalDec 2027Buntanetap · Phase 3$36M$2.8MSep 2026Ended Oct 2026$53M
Serina Therapeutics logo
Serina TherapeuticsSER · NYSE American
1 asset: 1 Ph 1SER-252 (PEOZ-apomorphine)Phase 1 · Parkinson's Disease31 Jan 2027SER-252 (PEOZ-apomorphine) · Phase 1$34M$19MSep 2026~3.4 qtrs$15M
Actinium Pharmaceuticals logo
Actinium PharmaceuticalsATNM ·
2 assets: 1 Ph 3, 1 Ph 2131I-apamistamabPhase 3 · Acute Myeloid LeukemiaPartial signalFeb 2029131I-apamistamab · Phase 2/3$34M$37MJun 2026~6.5 qtrs$18M
INmune Bio logo
INmune BioINMB · Nasdaq
1 asset: 1 Ph 2PegipanerminPhase 2 · Alzheimer's DiseasePartial signalNone on record$32M$16MSep 2026~5.1 qtrs$17M
NextCure, Inc. logo
NextCure, Inc.NXTC ·
3 assets: 1 Ph 2, 2 Ph 1NC410Phase 1/2 · Colorectal CancerDec 2027LNCB74 · Phase 1$32M$8.7MSep 2026~0.8 qtrs$26M
ProMIS Neurosciences, Inc. logo
ProMIS Neurosciences, Inc.PMN · Nasdaq
1 asset: 1 Ph 1PMN310Phase 1 · Alzheimer's DiseaseDec 2026PMN310 · Phase 1$28M$44MSep 2026~4.3 qtrs$33M
P
Pelthos Therapeutics Inc.PTHS · NYSE American
1 asset: 1 approvedApproved assets onlyNone on record$27M$18MSep 2026~2.2 qtrs$2.2M
Rockwell Medical logo
Rockwell MedicalRMTI · Nasdaq
1 asset: 1 approvedApproved assets onlyNone on record$25M$23MSep 2026Cash-flow positive$0.1M
ABVC BioPharma logo
ABVC BioPharmaABVC · Nasdaq
1 asset: 1 Ph 2PDC-1421Phase 2 · Major Depressive DisorderPartial signal28 Feb 2028PDC-1421 · Phase 1/2$24M$0.1MSep 2026Ended Oct 2026$0.1M
CervoMed Inc. logo
CervoMed Inc.CRVO · Nasdaq
1 asset: 1 Ph 2neflamapimodPhase 2 · Dementia with Lewy BodiesPartial signalNone on record$22M$20MSep 2026~2.9 qtrs$19M
Enlivex Therapeutics logo
Enlivex TherapeuticsENLV · Nasdaq
1 asset: 1 Ph 2AllocetraPhase 2 · OsteoarthritisFeb 2027Allocetra · Phase 2$20M$6.2MDec 2025Ended Aug 2026$9.2M
Palatin Technologies logo
Palatin TechnologiesPTN · NYSE
3 assets: 1 Ph 3, 2 Ph 2PL9643Phase 3 · Dry Eye DiseasePartial signalNone on record$20M$7.5MJun 2026~2.2 qtrs$12M
BeyondSpring Pharmaceuticals logo
BeyondSpring PharmaceuticalsBYSI · Nasdaq
1 asset: 1 Ph 3PlinabulinPhase 3 · Non-Small Cell Lung CancerPartial signal1 Jun 2029Plinabulin · Phase 3$19M$6.5MJun 2026Ended Nov 2026$4.6M
ATOSSA THERAPEUTICS, INC. logo
ATOSSA THERAPEUTICS, INC.ATOS · Nasdaq
1 asset: 1 Ph 2(Z)-endoxifenPhase 2 · HR+/HER2- Metastatic Breast CancerPartial signalNov 2026(Z)-endoxifen · Phase 2$18M$21MSep 2026~2.3 qtrs$19M
Lipocine Inc. logo
Lipocine Inc.LPCN · Nasdaq
1 asset: 1 approvedApproved assets onlyNone on record$17M$21MSep 2026~8.6 qtrs$9.5M
Marker Therapeutics, Inc. logo
Marker Therapeutics, Inc.MRKR ·
2 assets: 2 Ph 1NeldaleucelPhase 1 · Relapsed/Refractory Non-Hodgkin Lymphoma28 Feb 2028Neldaleucel · Phase 1$16M$12MJun 2026~4.9 qtrs$8.8M
Cellectar Biosciences, Inc. logo
Cellectar Biosciences, Inc.CLRB · Nasdaq
1 asset: 1 Ph 3Iopofosine I-131Phase 3 · Waldenstrom's MacroglobulinemiaWeak signal30 Jun 2027Iopofosine I-131 · Phase 1$15M$25MSep 2026~4.0 qtrs$16M
Seres Therapeutics logo
Seres TherapeuticsMCRB · Nasdaq
1 asset: 1 Ph 1SER-155Phase 1 · Bacterial Infections in Allogeneic Stem Cell TransplantNone on record$15M$21MSep 2026~1.3 qtrs$40M
Allarity Therapeutics, Inc. logo
Allarity Therapeutics, Inc.ALLR · Nasdaq
1 asset: 1 Ph 2stenoparibPhase 2 · Ovarian CancerMar 2027stenoparib · Phase 2$14M—~7.9 qtrsJun 2026$8.5M
Matinas BioPharma logo
Matinas BioPharmaMTNB · Nasdaq
1 asset: 1 Ph 3Amphotericin B (MAT2203)Phase 3 · Cryptococcal MeningitisNone on record$13M$0.8MJun 2026Ended Aug 2026$0.1M
BioCardia logo
BioCardiaBCDA · Nasdaq
1 asset: 1 Ph 3CardiAMPPhase 3 · Heart FailurePartial signal1 Apr 2027CardiAMP · Phase na$12M$2.2MSep 2026~1.2 qtrs$4.5M
Pluri Inc. logo
Pluri Inc.PLUR · Nasdaq
1 asset: 1 otherPLX-PADOsteoarthritisNone on record$11M$9.8MSep 2026~2.0 qtrs~$25M
Lisata Therapeutics logo
Lisata TherapeuticsLSTA · Nasdaq
2 assets: 2 Ph 2MAR001Phase 2 · HypertriglyceridemiaWeak signalNov 2027MAR001 · Phase 2$11M$283MSep 202610+ years$8.1M
Ainos, Inc. logo
Ainos, Inc.AIMD · Nasdaq
1 asset: 1 otherInterferon alfa (Veldona)Oral Warts in HIV PatientsNone on record$8.9M$1.4MJun 2026Ended Oct 2026$7.7M
VistaGen Therapeutics logo
VistaGen TherapeuticsVTGN · Nasdaq
3 assets: 1 Ph 3, 1 Ph 2, 1 otherfasedienolPhase 3 · Social Anxiety DisorderPartial signalNone on record$8.9M$20MSep 2026~1.4 qtrs~$48M
Kyntra Bio logo
Kyntra BioKYNB · Nasdaq
2 assets: 1 Ph 3, 1 Ph 1RoxadustatPhase 3 · Chronic Kidney DiseaseReliable signal30 Oct 2027Roxadustat · Phase 3$7.9M$91MJun 2026~9.6 qtrs$23M
Moleculin logo
MoleculinMBRX · Nasdaq
1 asset: 1 Ph 3AnnamycinPhase 2/3 · Acute Myeloid LeukemiaAug 2029Annamycin · Phase 2/3$7.2M$7.3MSep 2026~1.1 qtrs$20M
MetaVia logo
MetaViaMTVA · Nasdaq
2 assets: 1 Ph 2, 1 Ph 1VanoglipelPhase 2 · MASH / NASHWeak signalNone on record$7.1M$8.8MSep 2026~2.1 qtrs$19M
BioVie Inc. (NASDAQ: BIVI) logo
BioVie Inc. (NASDAQ: BIVI)BIVI · Nasdaq
1 asset: 1 Ph 3BezisterimPhase 3 · Alzheimer's DiseasePartial signalNone on record$7.1M$7.7MSep 2026~1.7 qtrs~$14M
Exicure, Inc. logo
Exicure, Inc.XCUR · Nasdaq
1 asset: 1 Ph 2Burixafor (TG-0054)Phase 2 · Multiple MyelomaWeak signalNone on record$6.8M$1.7MJun 2026Ended Oct 2026$2.0M
Tempest Therapeutics logo
Tempest TherapeuticsTPST · Nasdaq
1 asset: 1 Ph 3AmezalpatPhase 3 · Hepatocellular CarcinomaDec 2028Amezalpat · Phase 3$6.2M$0.9MSep 2026Ended Oct 2026$2.7M
Soligenix logo
SoligenixSNGX · Nasdaq
1 asset: 1 Ph 3Synthetic hypericinPhase 3Reliable signalNone on record$5.9M$9.0MSep 2026~4.7 qtrs$5.1M
Kiora Pharmaceuticals, Inc. logo
Kiora Pharmaceuticals, Inc.KPRX · Nasdaq
1 asset: 1 Ph 2KIO-301Phase 2 · Retinitis PigmentosaAug 2027KIO-301 · Phase 2$5.2M$16MSep 2026~8.4 qtrs$9.1M
Alzamend Neuro logo
Alzamend NeuroALZN · Nasdaq
1 asset: 1 Ph 2Lithium salicylate/L-proline (AL001)Phase 1/2 · Alzheimer's DiseaseWeak signalJul 2027Lithium salicylate/L-proline (AL001) · Phase 1/2$5.0M$7.6MJul 2026~4.7 qtrs~$4.3M
BioLineRx Ltd. logo
BioLineRx Ltd.BLRX · Nasdaq
1 asset: 1 approvedApproved assets onlyNone on record$5.0M$3.3MDec 2025Ended Oct 2026with a later raise$8.1M
Pulmatrix logo
PulmatrixPULM · Nasdaq
2 assets: 1 Ph 2, 1 Ph 1Itraconazole (PUR1900)Phase 2 · Allergic Bronchopulmonary AspergillosisNone on record$4.9M$2.2MJun 2026~2.2 qtrs<$0.1M
Processa Pharmaceuticals, Inc. logo
Processa Pharmaceuticals, Inc.PCSA · Nasdaq
1 asset: 1 Ph 2PCS499Phase 2 · Necrobiosis LipoidicaNone on record$4.8M$180MSep 202610+ years$6.4M
Lantern Pharma Inc. logo
Lantern Pharma Inc.LTRN ·
2 assets: 2 Ph 2DimesnaPhase 2 · Non-Small Cell Lung CancerPartial signalDec 2026Dimesna · Phase 2$4.7M$7.4MJun 2026~3.1 qtrswith a later raise$8.7M
Alaunos Therapeutics, Inc. logo
Alaunos Therapeutics, Inc.TCRT · Nasdaq
1 asset: 1 Ph 2DarinaparsinPhase 2 · Peripheral T-Cell LymphomaWeak signalNone on record$4.4M$0.1MJun 2026Ended Jul 2026$1.6M
GRI Bio, Inc. logo
GRI Bio, Inc.GRI · Nasdaq
1 asset: 1 otherGRI-0803Systemic Lupus ErythematosusNone on record$2.8M$9.5MSep 2026~4.0 qtrs$2.5M
Senti Biosciences logo
Senti BiosciencesSNTI ·
2 assets: 2 Ph 1SENTI-202Phase 1 · Acute Myeloid LeukemiaNone on record$2.7M$7.9MJun 2026Ended Sep 2026$31M
Jaguar Health logo
Jaguar HealthJAGX · Nasdaq
1 asset: 1 approvedApproved assets onlyDec 2026Crofelemer · Phase 2/3$1.7M$6.6MJun 2026~3.9 qtrs$25M
Curis logo
CurisCRIS ·
1 asset: 1 Ph 2EmavusertibPhase 2 · Acute Myeloid LeukemiaJul 2027Emavusertib · Phase 1/2$1.5M$5.6MSep 2026~0.7 qtrs$25M
Genprex, Inc. logo
Genprex, Inc.GNPX · Nasdaq
1 asset: 1 Ph 2Quaratusugene OzeplasmidPhase 1/2 · Non-Small Cell Lung CancerDec 2027Quaratusugene Ozeplasmid · Phase 1/2$1.4M$15MSep 2026~4.0 qtrs$10M
Aptevo Therapeutics logo
Aptevo TherapeuticsAPVO · Nasdaq
2 assets: 1 Ph 2, 1 Ph 1ALG.APV-527Phase 1/2 · Solid TumorsOct 2027Mipletamig · Phase 1$0.8M$9.8MJun 2026~1.6 qtrs$15M
3D Medicines Inc. logo
3D Medicines Inc.1244 · HKEX
2 assets: 2 Ph 3EnvafolimabPhase 3 · Non-Small Cell Lung CancerWeak signalDec 2026Envafolimab · Phase 2—$61MDec 2024~9.6 qtrs—
AB Science logo
AB ScienceAB · Euronext Paris
2 assets: 1 Ph 3, 1 Ph 2MasitinibPhase 3 · Alzheimer's DiseaseReliable signalDec 2027Masitinib · Phase 3—$10MJun 2026~5.6 qtrswith a later raise~$20M

Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.

Page123456789101112131415